In terms of breast cancer, multivariable MR analyses adjusting for body mass index and age at menarche suggested that genetically proxied inhibition of HMG-CoA reductase was associated with a reduced risk of breast cancer (OR: 0.85; 95% CI 0.75–0.95; P = 0.007). The gene discussed is HMGCR; the disease is breast carcinoma.